Interferon γ-release assays for detecting latent tuberculosis infection in patients scheduled for anti-TNFα therapy
- Correspondence to Ms Kay Greveson, Centre for Gastroenterology, Royal Free Hospital, Pond St, London NW3 2QG, UK;
- Accepted 22 September 2010
- Published Online First 20 November 2010
Screening for, and treatment of, latent tuberculosis infection (LTBI) before anti- tumour necrosis factor α therapy has been shown to decrease the incidence of active tuberculosis by more than 80% and is recommended before initiation of treatment. In the absence of a ‘gold standard’ test for LTBI, current screening involves taking a clinical history of risk factors, chest radiograph and tuberculin skin test. Alternative cellular immune-based screening tests have been developed to detect Mycobacterium tuberculosis infection. This paper summarises the current position and advances in the use of newer screening strategies for LTBI.
Competing Interests None.
Provenance and peer review Commissioned; externally peer reviewed.